Employer GLP-1 Coverage: How to Push HR to Add the Benefit

Your insurance doesn't cover Wegovy. You've verified with the pharmacy — denied for weight loss. You're paying $199/month via TrumpRx (not bad, but not as good as the $50 copay your covered coworkers get). You wonder if there's anything you can do about it.

There is. Employer-sponsored GLP-1 coverage is a decision your company made — typically on cost grounds — and it's a decision that can be changed. Employers add the benefit when enough employees push for it, when the cost-benefit math works for them, and when their benefits consultants build the case.

Here's the playbook. Realistic expectations, specific scripts, and the data that actually moves HR decisions.

Why most employers don't cover GLP-1s for weight loss

Employer health plans (especially self-insured plans at mid-to-large companies) make coverage decisions based on projected per-member-per-month cost. GLP-1 coverage for weight loss has historically looked expensive:

• Utilization rates among eligible employees are high (15–30% of employees meet BMI criteria).
• List prices were $800–$1,400/month.
• Annual cost per utilizing employee: $10,000–$15,000.
• If 20% of 1,000 employees use the benefit: $2M–$3M in annual drug spending.

This math scared employers off. The response from benefits consultants and CHROs was typically: "Let's wait and see on coverage."

What's changed in 2026

The math has shifted considerably:

• TrumpRx and direct-to-consumer pricing: Brand-name GLP-1 costs have dropped from $1,300 list to $199–$350 direct-to-consumer. Negotiated PBM pricing for employer plans is often similar.¹
• Cardiovascular outcomes data: SELECT trial established 20% MACE reduction, giving employers a clearer "prevented event" story.²
• Medicare coverage expansion: The Trump administration extended Medicare Part D coverage to obesity in 2026, which effectively normalizes GLP-1s as treatment for a chronic disease rather than a cosmetic intervention.
• Employee demand: GLP-1 coverage has become a recruiting and retention factor in competitive labor markets.
• PBM competition: Pharmacy benefit managers have developed more cost-controlled GLP-1 programs for employers.

A 2026 business case for employer GLP-1 coverage looks different — and better — than a 2023 business case. HR departments that haven't revisited the decision recently are operating on outdated math.

The types of employers most likely to add coverage

• Large employers (5,000+ employees). Economies of scale on PBM negotiation, and typically better benefits programs overall.
• Self-insured employers. Flexible formulary decisions; can add specific drugs without waiting for carrier decisions.
• Technology companies. Competitive for talent, usually better benefits.
• Healthcare employers. Employees are often the most educated advocates; leadership often understands the clinical case.
• Union employers. Collective bargaining has specifically added GLP-1 coverage in several high-profile 2025–2026 contracts.
• Industries with high obesity burden. Companies with high healthcare spending find the ROI math compelling.

If you work for one of these, your chances of getting coverage added are higher. If you work for a small business, a heavily cost-conscious company, or a place that recently dropped coverage, the bar is higher.

The playbook: steps in order

Step 1: Confirm coverage status and the specific exclusion

Before launching an advocacy campaign, get the precise coverage status:

• Call your insurance (member services, not HR).
• Ask: "Is Wegovy or Zepbound covered on my formulary?"
• Ask: "What's the specific exclusion reason?" Common ones: "weight loss excluded," "not on formulary," "prior auth required but typically denied."
• Document everything in writing (screenshots of portal, emails).

Step 2: Identify your point person

Figure out who makes benefits decisions at your company:

• At small companies (under 200 employees): usually the CEO or CFO, with HR input.
• At mid-sized companies: VP of HR or Head of Total Rewards.
• At large companies: Director of Benefits or Head of Benefits.
• At very large companies: a full Benefits team with a defined renewal process.

LinkedIn search "[company name] benefits" often surfaces the right name.

Step 3: Request a meeting — individually or as a group

Email script for an individual request:

Email script for a group request (stronger):

Step 4: Prepare the business case

What moves HR is data, not passion. Your meeting package:

• 2026 pricing data. TrumpRx, direct-to-consumer, Medicare coverage — all suggest PBM-negotiated rates for employers are lower than they used to be.
• Cardiovascular evidence. SELECT trial 20% MACE reduction. Clear prevention ROI.
• Productivity data. Peer-reviewed evidence on obesity-related absenteeism and presenteeism.
• Competitor benefits data. List of major companies and competitors in your industry that cover GLP-1s (often published in HR media like SHRM, WTW, Mercer reports).
• Cost modeling. Rough estimate of the annual cost of coverage vs. projected healthcare savings from reduced cardiometabolic events.
• Employee demand evidence. If you've spoken to multiple employees interested, note it (don't overclaim).

Step 5: Address the likely objections

Prepare responses for the concerns HR will raise:

• "Cost too high." Point to 2026 pricing collapse, TrumpRx data, negotiated PBM rates. Note that the expensive version of the decision was 2022–2024; 2026 is different.
• "High utilization rate." True, but that's the point — it means the benefit creates the most value. High utilization = high impact.
• "No long-term data." 20+ years of diabetes safety data for the drug class. 5+ years of weight-loss-dose data. Longer follow-up than most new benefits.
• "Adverse selection risk." Self-insured employers do see selection effects, but the effect size is bounded by eligibility criteria (BMI thresholds).
• "Would open doors to other cosmetic medications." Current AMA guidance treats obesity as a disease, not a cosmetic condition. This framing should push back on the cosmetic argument.
• "Our broker said no." Brokers have their own incentives. Ask them to show the 2026 updated analysis. Many brokers haven't refreshed their models.

Step 6: Ask for a specific, small next step

Don't ask for "please add Wegovy to the formulary." Ask for:

• "Could you ask our broker / benefits consultant to provide an updated cost analysis for 2026?"
• "Could this be on the agenda for the next benefits renewal meeting?"
• "Could we pilot coverage in a limited form — BMI ≥35 with comorbidity, for example — and expand based on results?"
• "Could we add GLP-1s to a wellness incentive program with shared cost?"

Small asks get yes. Big asks get studies.

If you're at a small company

Small companies don't negotiate formularies directly; they buy from fully-insured plans offered by carriers. Your leverage is different:

• Ask HR: "Do we have any employees currently paying out of pocket for weight-management medications? What if we shifted plan brokers to one with better GLP-1 coverage?"
• Identify specific competing plans (same carrier, different tier) that cover GLP-1s.
• Frame it as "upgrading our plan to better match competitive benefits" rather than "adding a new benefit."
• Accept that the answer may be "we can't change mid-year" — then ask to be included in next year's renewal conversation.

The wellness program path

Some employers add GLP-1 coverage through wellness programs rather than through the main formulary. This is often a politically easier path:

• Coverage conditional on participation in a weight management program.
• Coverage with step therapy (try Phentermine first, then GLP-1).
• Coverage tied to BMI threshold + physician documentation.
• Coverage with a 6-month employment tenure requirement.

These conditions reduce adverse selection and make the cost more predictable — a compromise between "no coverage" and "unrestricted coverage."

The things not to do

What happens next

Realistic outcomes:

• Best case: HR schedules a formal review with the benefits consultant. Coverage added at next renewal.
• Likely case: HR acknowledges the request, notes it for the renewal conversation, no immediate change. Revisit in 6 months.
• Common case: "We're looking at it but cost is an issue." Continue to advocate; the conversation matters even without immediate yes.
• Disappointing but not rare case: "It's not currently in the plan." No follow-up. Raise it again next renewal.

Most employer coverage additions happen at annual renewal, not mid-year. Plan your advocacy to align with your company's benefits cycle.

If you succeed

If coverage is added:

• Thank the HR contact publicly but specifically — helps them justify similar future decisions.
• Help other employees navigate the new coverage.
• Provide feedback to HR on how the benefit is working, especially at the 6- and 12-month mark.
• Share aggregate positive outcome data with HR (no PHI — just "10 of us got coverage, 9 of us are still using it and healthier").

Benefits that get visibly utilized and appreciated tend to stick. Benefits that get added quietly and never acknowledged often get pulled in later rounds of cost-cutting.

If they say no

Alternatives if employer coverage isn't coming:

• TrumpRx direct-to-consumer at $199/month — cheapest brand-name path.
• HSA-eligible compounded or brand via telehealth — tax-advantaged reduction.
• Spouse's coverage — if their employer covers.
• Marketplace ACA plans — some cover GLP-1s for weight loss.
• Individual tax-advantaged planning — HSA contributions maxed out, dollars used for GLP-1.

No employer is the end of the world. Self-pay at 2026 prices is manageable for most men with middle-class incomes. But employer coverage remains the gold standard because the math is unbeatable — $25–$100/month copay vs. $200+/month self-pay.

The bottom line

Employer GLP-1 coverage is a lever that more employees can move than realize. The 2026 cost-benefit analysis is fundamentally different from the 2022 analysis, and many HR departments haven't updated their models. A reasonable, data-driven, professional advocacy approach succeeds more often than the passive "my company just doesn't cover it" resignation.

If you work for a large self-insured employer, push. If you work at a small company, ask to be part of the next renewal conversation. If coverage is added, help make it visible and valued. If it's not, TrumpRx at $199/month has made self-pay more affordable than it's ever been.

The era of "either employer covers or I can't afford it" is ending. Coverage still helps enormously — but the cliff between covered and uncovered has flattened significantly. Either way, you have options that didn't exist in 2023.